Stocks and Investing Stocks and Investing
Fri, April 14, 2023

Uy Ear Reiterated (ACAD) at Hold and Held Target at $20 on, Apr 14th, 2023


Published on 2024-10-28 02:45:14 - WOPRAI, Uy Ear
  Print publication without navigation


Uy Ear of Mizuho, Reiterated "ACADIA Pharmaceuticals Inc." (ACAD) at Hold and Held Target at $20 on, Apr 14th, 2023.

Uy has made no other calls on ACAD in the last 4 months.



There are 11 other peers that have a rating on ACAD. Out of the 11 peers that are also analyzing ACAD, 6 agree with Uy's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Julio Romero of "JP Morgan" Maintained at Hold with Increased Target to $21 on, Monday, March 20th, 2023
  • Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $21 on, Tuesday, March 14th, 2023
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold and Held Target at $23 on, Tuesday, March 14th, 2023
  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $20 on, Tuesday, March 14th, 2023
  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $20 on, Wednesday, March 1st, 2023
  • Jason West of "JMP Securities" Maintained at Hold with Decreased Target to $22 on, Tuesday, February 28th, 2023


These are the ratings of the 5 analyists that currently disagree with Uy


  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $26 on, Tuesday, March 14th, 2023
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $28 on, Tuesday, March 14th, 2023
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $33 on, Tuesday, March 14th, 2023
  • Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $27 on, Tuesday, March 14th, 2023
  • Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $22 on, Tuesday, January 3rd, 2023
Contributing Sources